--- title: "Cytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit" url: "https://aibio.space/news/cytokinetics-sues-bristol-myers-squibb-myokardia-delaware-patent-suit/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-13" section: "Legal" tickers: "NASDAQ:CYTK" source: "https://www.sec.gov/Archives/edgar/data/1061983/000119312526348060/cytk-20260813.htm" summary: "Cytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and t" --- By the aibio.space news desk. Sources - [CYTOKINETICS INC Form 8-K filed August 13, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526348060/cytk-20260813.htm) - [CYTOKINETICS INC Form 10-K filed February 26, 2026: business overview and signatures (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm) [CYTK](https://aibio.space/companies/cytokinetics/) 2026-08-13 # Cytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit over MYQORZO Tickers [CYTK](https://aibio.space/companies/cytokinetics/) Cytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The defendants are Bristol-Myers Squibb and MyoKardia. ## Key facts - **Company**: Cytokinetics, Incorporated (NASDAQ: CYTK) - **News type**: Legal - **Primary source**: [CYTOKINETICS INC Form 8-K filed August 13, 2026 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526348060/cytk-20260813.htm) *The Capitol dome and spring blossom. Photo: Angie Drake, CC0, via Wordpress. The picture shows the field, not the companies named.* Cytokinetics, Incorporated (Nasdaq: [CYTK](https://aibio.space/companies/cytokinetics/)) filed a patent lawsuit on August 13, 2026, against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint was filed in the United States District Court for the District of Delaware. Cytokinetics disclosed it in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1061983/000119312526348060/cytk-20260813.htm) the same day. Cytokinetics is the plaintiff. The defendants are Bristol-Myers Squibb and MyoKardia, which the filing does not describe further. The 8-K gives no case number. ## What the complaint asks for The complaint seeks a declaratory judgment that Cytokinetics does not infringe U.S. Patent No. 12,616,697, which the filing calls the '697 patent, and that the patent's claims are invalid. It also asks for a judgment preliminarily and permanently enjoining the defendants, and those acting in concert with them, from threatening or starting infringement litigation against Cytokinetics or against users, customers, dealers, suppliers, sellers or distributors of its MYQORZO (aficamten). The company asks for its costs and for attorneys' fees under 35 U.S.C. § 285, which applies in exceptional cases. It has demanded a jury trial on all triable issues. The 8-K does not say when the patent was issued, what product or claim the defendants have asserted against Cytokinetics, or whether any demand letter came before the suit. It also does not give damages or a dollar amount in dispute. The company says it "intends to vigorously assert its legal rights" but that "the outcome of any litigation is inherently uncertain." It says it will provide updates in its SEC filings to the extent required or appropriate and does not otherwise intend to comment. John O. Faurescu, SVP, Deputy General Counsel & Secretary, signed the 8-K. ## The product at stake MYQORZO is Cytokinetics' first commercial product. The company's [annual report for 2025](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm) says the U.S. Food and Drug Administration approved it in December 2025, in 5, 10, 15 and 20 mg tablets. MYQORZO is an allosteric, reversible inhibitor of cardiac myosin, and the approval included a risk evaluation and mitigation strategy. Sanofi is responsible for development and commercialization of aficamten in China, where it is to be commercialized as MYQORZO. Bayer Consumer Care AG holds an exclusive license for Japan. The annual report also says the milestones and royalties it may receive from Sanofi and Bayer depend on those partners' efforts to commercialize aficamten. It also describes financing arrangements with Royalty Pharma, including revenue participation rights on aficamten and a development funding loan. ## The company's finances The annual report gives a net loss of $785.0 million for 2025, compared with $589.5 million for 2024. The statement of operations in the same report shows the 2025 net loss as $784,955 thousand, which includes a debt conversion expense of $121,249 thousand. The company used $510.0 million in operations in 2025, compared with $395.9 million in 2024. Cash and cash equivalents were $122.5 million at December 31, 2025, and short-term investments were $759.7 million. The latest quarterly figures, for the period ended June 30, 2026, show cash and cash equivalents of $255.3 million and short-term investments of $910.4 million. The quarterly report was filed August 6, 2026, before the lawsuit. The 8-K contains no statement on how the lawsuit's cost will be paid or how it would affect the commercial launch of MYQORZO. It does not say whether Cytokinetics has recorded any reserve for the case, and it does not address a possible loss. ## What comes next The complaint is at the start of the process. The filing does not say when the defendants must respond, or when a trial might be scheduled. The 8-K does not say who owns the '697 patent or what the defendants have said about it. Cytokinetics is asking a Delaware court to clear the way for its first product while it is still losing money, and its own filing treats the outcome as uncertain. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story CYTK Cytokinetics, Incorporated NASDAQ · United States Open the starter desk ## More in Legal Legal ### [Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena](https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/) Oct 29, 2026 Legal ### [Viking and Ligand dispute VK2809 license termination in San Diego court](https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/) Oct 29, 2026 Legal ### [Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit](https://aibio.space/news/vikings-itc-trade-secret-ruling-against-ascletis-appeal-federal/) Oct 29, 2026 --- Source page: https://aibio.space/news/cytokinetics-sues-bristol-myers-squibb-myokardia-delaware-patent-suit/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cytokinetics sues Bristol-Myers Squibb and MyoKardia in Delaware patent suit", 2026-08-13, https://aibio.space/news/cytokinetics-sues-bristol-myers-squibb-myokardia-delaware-patent-suit/